LOTEMAX (loteprednol etabonate) by Bausch + Lomb is clinical pharmacology corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. First approved in 1998.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
LOTEMAX (loteprednol etabonate) is a corticosteroid ophthalmic suspension that inhibits inflammatory response by inducing phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene mediators. It is formulated as eye drops for treatment of post-operative anterior chamber inflammation, giant papillary conjunctivitis, seasonal allergic conjunctivitis, and uveitis. The drug undergoes extensive hepatic metabolism to inactive carboxylic acid metabolites with minimal systemic absorption.
As a product approaching loss of exclusivity in the mature ophthalmic corticosteroid market, LOTEMAX teams are likely focused on defending market share against generics and managing portfolio transition.
CLINICAL PHARMACOLOGY Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen,…
Worked on LOTEMAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation
LOTEMAX roles are concentrated in commercial defense and market access functions as the product approaches LOE; this is a stable but declining career opportunity with emphasis on generic competitive positioning and payer negotiations rather than growth. Professionals joining LOTEMAX teams should expect focus on protecting existing market share, optimizing pricing, and managing transition strategies.